- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2022-06-23
2026-10
2026-10
500
NCT05403177
University Health Network, Toronto
University Health Network, Toronto
OBSERVATIONAL
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2022-05-30 | N/A | 2025-01-29 |
2022-05-30 | N/A | 2025-02-03 |
2022-06-03 | N/A | 2025-01 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
| : MOHCCN-O Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging |
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data | Consolidate and annotate data from patients included in a pan-Canadian cohort | 5 years |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases | Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases. | 5 years |
| Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions | Health technology assessment tools will be used to evaluate the real-world value of precision medicine | 5 years |
| Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine | Health technology assessment tools will be used to evaluate the real-world value of precision medicine | 5 years |
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
|
Study Contact Name: PM2C Central Office Phone Number: 416-946-4501 Email: MOHCCN@uhn.ca |
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
18 Years
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
No publications available
